Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 9/20 | 0.54 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.52 |
| ▸ | YARS1 | P54577 | 2/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | CPA1 | P15085 | 1/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30326195 | 0.94 | MME (0.60) | MMESLC7A5YARS1OPRD1ENPEP | |
| SCHEMBL7149290 | 0.94 | MME (0.60) | MMESLC7A5YARS1OPRD1ENPEP | |
| SCHEMBL7149294 | 0.94 | MME (0.60) | MMESLC7A5YARS1OPRD1ENPEP | |
| SCHEMBL30957419 | 0.93 | MME (0.55) | MMESLC7A5OPRM1OPRD1ENPEP | |
| SCHEMBL30390719 | 0.93 | MME (0.55) | MMESLC7A5OPRM1OPRD1ENPEP | |
| SCHEMBL30287990 | 0.92 | MME (0.60) | MMESLC7A5YARS1OPRM1OPRD1 | |
| SCHEMBL30287993 | 0.92 | MME (0.60) | MMESLC7A5YARS1OPRM1OPRD1 | |
| SCHEMBL31025679 | 0.92 | MME (0.60) | MMESLC7A5YARS1OPRM1OPRD1 | |
| SCHEMBL31031588 | 0.91 | SLC7A5 (0.56) | MMESLC7A5YARS1OPRM1OPRD1 | |
| SCHEMBL30390365 | 0.90 | MME (0.57) | MMESLC7A5ENPEPACECPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240076314-A1 | PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | GLO PHARMA, INC. | 2024-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240076314-A1 | PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | CHRNB1, CHRNG, CHRNA1 | MME 402/4885SLC7A5 2306/4885YARS1 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.